Acute Effect of „electronic – cigarette“-use on vascular endothelial function

Acute Effect of „electronic – cigarette“-use on vascular endothelial function - VaPOR-Acute

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00007930

Enrollment

Registered

2015-05-05

Start date

2015-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy volunteers nicotine dependence

Interventions

Group 1: Non-Smokers FMD before and after inhalation (20 min)of e-cigarette vapor with nicotine (18 µg/ml) Group 2: Non-Smokers FMD before and after inhalation (20 min)of e-cigarette vapor with nicoti

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Non-smokers and smokers age 18-60

Exclusion criteria

Exclusion criteria: •Smoking of tobacco products within the preceding 6 months (only cohort 1) •Current use of long acting nitrates or calcium antagonists •History of asthma or chronic pulmonary disease •Vascular or other abnormalities precluding application of a pressure cuff on the arm to conduct FMD/FMC measurement •symptomatic cardiovascular disease

Design outcomes

Primary

Measure	Time frame
Endothelial function (flow-mediated dialtion FMD % of A. brachialis) as change before and after vapor exposition measured with high resolution ultrasound before and after cuff occlusion as described in guidelines.	—

Secondary

Measure	Time frame
FMC (flow mediated contraction as described by Gori measured by ultrasound corresponding to FMD) measured before and after vapor exposure; blood pressure measured with Riva-Roci and contiously before , during and after vapor exposure using pulse transit time heart rate (ECG derived, holter monitoring before and during exposure) sympathic nerve activity (laser Doppler before and after exposure) sympathovagal Balance (derived from ECG heart variability measured with holter ECG during study period) oxdiative Stress (blood) Effect of antioxidative substances on FMD (measured as effect of p.o. VitC application on FMD after exposure) Endothelium activation (measured in blood before and after vapor from frozen samples with the use of ELISA kits (E-selectine, VCAM etc.)) Oxidative stress (measured from frozen blood samples befor and after exposure with ELISA kits TBARS, MDA, OxLDL, MPO)	—

Measure

Time frame

FMC (flow mediated contraction as described by Gori measured by ultrasound corresponding to FMD) measured before and after vapor exposure; blood pressure measured with Riva-Roci and contiously before , during and after vapor exposure using pulse transit time heart rate (ECG derived, holter monitoring before and during exposure) sympathic nerve activity (laser Doppler before and after exposure) sympathovagal Balance (derived from ECG heart variability measured with holter ECG during study period) oxdiative Stress (blood) Effect of antioxidative substances on FMD (measured as effect of p.o. VitC application on FMD after exposure) Endothelium activation (measured in blood before and after vapor from frozen samples with the use of ELISA kits (E-selectine, VCAM etc.)) Oxidative stress (measured from frozen blood samples befor and after exposure with ELISA kits TBARS, MDA, OxLDL, MPO)

—

Countries

Germany

Contacts

Public ContactHannelore Seiler

Universitätsmedizin Mainz

Hannelore.Seiler@unimedizin-mainz.de06131-172476

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026